
Novozymes Biopharma's Technology Demonstrates Potential for Monthly Drug Dosing
Novozymes Biopharma has released new study data on extending the serum half-life of albumin in vivo.
Novozymes Biopharma has
By modifying the human albumin molecule, Novozymes managed to alter the affinity of albumin to the FcRn receptor. Extended serum half-life was observed for a range of albumin variants. The platform has the potential to provide patients with better quality of life through tailoring drug circulatory half-life to meet specific medical needs, while improving patient compliance and reducing healthcare costs.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.